LTR Pharma (ASX:LTP) Gross-Profit-to-Asset % : 0.66% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LTR Pharma's annualized Gross Profit for the quarter that ended in Dec. 2024 was A$0.13 Mil. LTR Pharma's average Total Assets over the quarter that ended in Dec. 2024 was A$19.05 Mil. Therefore, LTR Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.66%.

LTR Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for LTR Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Gross-Profit-to-Asset % Chart

LTR Pharma Annual Data

Trend

Jun24

Gross-Profit-to-Asset %

LTR Pharma Semi-Annual Data
	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	-	-	0.66

Competitive Comparison of LTR Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, LTR Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

LTR Pharma Gross-Profit-to-Asset % Calculation

LTR Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: . 20 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

LTR Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0.126	/	( (3.369	+	34.732)	/ 2 )
	=	0.126	/	19.0505
	=	0.66 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LTR Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines